Breaking News
0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

BioNTech SE Slides on Vaccine Revenue Miss But Consensus Was 'Too High'

Stock Markets Aug 08, 2022 15:40
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters
 
BNTX
+2.08%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Sam Boughedda

BioNTech SE (NASDAQ:BNTX) shares tumbled more than 9% Monday after reporting second-quarter earnings before the open.

The drugmaker posted second-quarter earnings of €6.45 per share on revenue of €3.2 billion. Earnings and revenue fell from the second quarter of 2021, where it reported a profit of €10.77 per share on revenue of $5.3 billion.

"With our strong performance year to date, we believe to be well on track to achieve our previous financial guidance for the ongoing financial year," said Jens Holstein, CFO of BioNTech. "With our initiatives around variant-adapted COVID-19 vaccine candidates, we expect an uptake in demand in our key markets in the fourth quarter of 2022, subject to regulatory approval."

The company reiterated BioNTech COVID-19 2022 vaccine revenue guidance of between €13 billion and €17 billion.

Following the report, a Morgan Stanley analyst released a research note maintaining an Equal-Weight rating and $194 price target on BioNTech shares. The analyst said vaccine sales were 18% below consensus.

"Total product sales were €3.2B vs. €3.9B consensus (visible alpha). COGS increased to 24% sequentially (up from 20% in 1Q) due to a ~€400M write-off, the transition of manufacturing capacity to variant specific boosters and the consolidation of the CMO network. Mgt. ended 2Q with cash of €9.3B and trade receivables of €10.4B which we expect to turn into cash in the next 1-2 quarters," said the analyst. "Mgt. reiterated 2022 COVID vaccine revenue guidance of €13-17B (~2.5Bbn doses). Mgt. expects revenue phasing to be more heavily weighted to 4Q vs 3Q as Omicron-adapted boosters begin to ship. Other guidance also remained unchanged."

He concluded: "BNTX is underperforming today on the vaccine revenue miss, but consensus was likely too high given mgt. had already highlighted changes in the EU order pattern and delays with COVAX. We are leaving our numbers unchanged, but do expect 3Q to be lower than 2Q and 4Q to be more similar to 1Q. Overall, BA.4/5 regulatory approvals, PCV data in 1H23 and potential cash deployment remain the key drivers of BNTX."

BioNTech SE Slides on Vaccine Revenue Miss But Consensus Was 'Too High'
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email